About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to adv ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025, in Barcelona, Spain ...

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Tiziana Life Sciences Ltd is one of them. Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotech company focused on next-generation immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis, Alzheimer’s, and multiple system atrophy. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to stimulate ...

伯克希尔哈撒韦与比亚迪股份 - 伯克希尔哈撒韦已清仓比亚迪股份 截至2025年3月31日投资价值列为0[1][10] - 巴菲特自2008年9月起累计减持比亚迪H股至少16次 套利至少80.71亿港元[1][10] - 伯克希尔2008年以每股8港元认购2.25亿股 持股14年后于2022年8月开始减持[10] 华为鸿蒙生态发展 - HarmonyOS 5终端设备数量突破1700万台[8] - 正式启动"天工计划" 将投入10亿元人民币支持鸿蒙AI生态创新[8] 优必选全球合作 - 与云智汇科技签署全球战略合作协议 明确人形机器人研发与市场推广分工[13] - 云智汇负责全球销售与售后服务 优必选专注研发生产与技术升级[13] 特斯拉法律纠纷 - 7名车主起诉特斯拉欺诈 因FSD功能未兑现要求退费及三倍赔偿[14] - 案件已由北京市大兴区人民法院立案 正在等待一审开庭[14] 预制菜行业监管 - 国务院食安办等部门推进预制菜国家标准制定[3][4] - 要求餐饮环节使用预制菜明示 维护消费者知情权与选择权[4] 企业资本运作 - 中油工程子公司签署5.13亿美元阿联酋LNG输送管线项目合同[16] - 林洋能源预中标1.42亿元国家电网采购项目[16] - 多家上市公司披露股份回购与减持计划 包括东峰集团累计回购0.70%股份[16] 企业并购动态 - 金帝股份拟收购优尼精密控股权[17] - 向日葵拟购买兮璞材料100%股权 股票将于9月22日复牌[17] - 华海诚科发行股份购买资产获证监会注册批复[17]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the U.S. Department of Defense (DoD) has awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). This funding builds on Tiziana’s strategy t ...

BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 193,848 shares of Tiziana common stock at a price of $1.65 per share in the open market. About Foralumab Foralumab, a fully human anti-CD3 m ...